Trials like the dostarlimab study in rectal cancer and NICHE in colon cancer show neoadjuvant immunotherapy can induce profound responses in MSI-high tumors. This is creating a new paradigm where major surgery might be avoided entirely for some patients, marking a significant shift in treatment strategy.

After numerous failures to make immunotherapy effective in microsatellite-stable (MSS) metastatic colorectal cancer, the STELLAR-303 trial shows a statistically significant survival benefit for zenzalintinib plus atezolizumab over regorafenib. This marks a potential breakthrough, offering a new IO-based option for this large patient population.

In PD-L1 negative KRAS-mutated lung cancer, where standard immunotherapy is less effective, adding a CTLA-4 inhibitor can recover the immune response and create long-term survivors. This makes a triplet or quadruplet regimen the current optimal strategy for this challenging patient subgroup.

The STELLAR-303 trial is the first to show an immunotherapy-based regimen provides an overall survival benefit in microsatellite-stable CRC. Crucially, this benefit extends to patients with liver metastases, a subgroup that has historically shown profound resistance to immunotherapy, highlighting the drug's novel mechanism.

Unlike in rectal cancer where pre-surgical shrinkage is key, the primary objective of neoadjuvant immunotherapy in operable colon cancer is to activate a systemic immune response. This targets and eliminates unseen micro-metastases, the true cause of recurrence, thereby increasing the overall cure rate.

While immunotherapy is largely ineffective in metastatic microsatellite stable (MSS) colorectal cancer, emerging data suggests it may have surprising efficacy in the early-stage (neoadjuvant) setting. This differential response is likely due to a more favorable tumor microenvironment in earlier disease, suggesting a new therapeutic window.

Antibody-drug conjugates can disrupt the tumor microenvironment, leading to an influx of immune cells. This may turn an immunologically "cold" tumor "hot," creating a rationale for re-challenging with an immune checkpoint inhibitor, even if the patient's tumor previously did not respond to one.

The traditional CRC treatment path (chemo-surgery-chemo) is being upended. New data shows giving immunotherapy before surgery can be so effective that the surgery itself becomes the "adjuvant" or follow-up treatment, representing a major paradigm shift.

To combat immunosuppressive "cold" tumors, new trispecific antibodies are emerging. Unlike standard T-cell engagers that only provide the primary CD3 activation signal, these drugs also deliver the crucial co-stimulatory signal (e.g., via CD28), ensuring full T-cell activation in microenvironments where this second signal is naturally absent.